INTRODUCTION {#s1}
============

Gastric cancer (GC) is the fourth most common cancer in the world and the second most common cause of cancer-related death \[[@R1]\]. Although remarkable improvement has been made in surgical treatment, the survival of GC still remains poor, with the overall 5-year survival rate for gastric cancer approximately 27.4% in China \[[@R2]\]. Moreover, patients with the same TNM (tumor/node/metastasis) stage and treatment may demonstrate various clinical outcomes. As a complex disease, the initiation and progression of GC is strongly influenced by both genetic and environmental factors \[[@R3], [@R4]\]. Therefore, identification of genetic biomarkers that could predict prognosis of GC patients would greatly benefit the individualized therapy, post-operational treatment and follow-up strategies \[[@R5]\].

DNA repair systems play a pivotal role in maintaining the stability and integrity of the genome, which include nucleotide excision repair (NER), base excision repair (BER), mismatch repair (MMR) and double-strand break repair (DSBR) \[[@R6], [@R7]\]. Nucleotide excision repair (NER) is a versatile system that monitors and repairs DNA damage caused by both endogenous and exogenous factors, including therapeutic agents \[[@R8]\]. As a result, the alternation of NER capacity could contribute to the different clinical outcomes of GC patients. NER process include steps of damage recognition, damage demarcation and unwinding, damage incision, and new strand ligation, all of which require corresponding functional proteins \[[@R9]\]. XPA, XPC and DDB2 are responsible for the DNA damage recognition \[[@R10], [@R11]\]; ERCC2 and ERCC3 participate in the damage unwinding process \[[@R12], [@R13]\]; ERCC1, ERCC4 and ERCC5 are involved in the DNA damage incision \[[@R14], [@R15]\]. In addition, ERCC6 and ERCC8 are both essential factors involved in transcription-coupled NER \[[@R16], [@R17]\].

Polymorphisms of core NER genes could change the NER ability by influencing the expression and function of important proteins, thereby altering individual survival of GC patients. Driven by such hypothesis, polymorphisms of several NER genes have previously been studied in relation to the prognosis of GC patients \[[@R18]\]. For example, Liu et al. studied *ERCC1* rs11615 C/T polymorphism and found that CT/TT genotype was significantly associated with worse prognosis compared with the CC genotype by evaluating overall survival (OS) in Chinese \[[@R19]\]. Han et al. investigated *ERCC1* rs3212986 A/C polymorphism in Korean population and revealed that GC patients with the CC genotype had longer OS than CA/AA carriers \[[@R20]\]. In addition, Zou et al. investigated the *ERCC5* rs17655 C/G polymorphism and found that GC patients with the CT/TT genotype had longer OS compared with CC genotype carriers in Chinese \[[@R21]\]. Although several NER polymorphisms have been reported to be related with survival of GC patients, most of these studies investigated only a few SNPs of a single NER gene. The association of NER gene polymorphisms with GC prognosis at the level of entire pathway and the joint effect of different polymorphisms of NER pathway genes remains largely unknown.

Until now, no study has yet been performed concerning the role of polymorphisms from perspective of the whole NER pathway in the prognosis of GC. In the present study, therefore, we systematically analyzed the association of 43 SNPs of ten key NER pathway genes (*ERCC1*, *ERCC2*, *ERCC3*, *ERCC4*, *ERCC5*, *ERCC6*, *ERCC8*, *XPA*, *XPC*, and *DDB2*) with survival of GC patients to investigate whether NER pathway polymorphisms could serve as potential biomarkers for GC prognosis.

RESULTS {#s2}
=======

Clinicopathological characteristics and OS of GC {#s2_1}
------------------------------------------------

A total of 373 patients including 263 (70.5%) males and 110 (29.5%) females were enrolled in the present study. The age of GC diagnosis ranged from 29 to 87 with a mean age of 58.8±10.2 years. At the last follow-up (September 2014), 114 patients died, with a median overall survival of 58.6 months. Among the patients, 184 (49.3%) presented with stages I-II and 189 (50.7%) with stages III-IV; 228 (61.1%) subjects were lymphatic metastasis positive while 145 (38.9%) patients were negative.

The effect of clinicopathological characteristics on survival of GC patients was summarized in Table [1](#T1){ref-type="table"}. TNM stage (*P*\<0.001), lymphatic metastasis (*P*\<0.001), Borrmann classification (*P*=0.015) were all significant prognostic factors. No significant association was observed of Lauren\'s classification, alcohol drinking and smoking with GC survival. Therefore, multivariate analysis was subsequently performed using Cox\'s proportional hazards model adjusted by age, gender, TNM stage, lymphatic metastasis and Borrmann classification in order to identify independent prognostic value of polymorphism in NER pathway genes.

###### Clinicopathological characteristics and OS of GC

  Variables                  Patients(%)   Deaths   MST(month)   HR(95%CI)          P
  -------------------------- ------------- -------- ------------ ------------------ ---------
  Age                                                                               
   ≦60                       159(42.6)     65       60.6         1(Ref)             
   \>60                      214(57.4)     49       52.5         1.08(0.74-1.56)    0.692
  Gender                                                                            
   Male                      263(70.5)     80       58.7         1(Ref)             
   Female                    110(29.5)     34       44.8         0.95(0.64-1.42)    0.803
  Growth pattern                                                                    
   Expanding                 27(9.2)       3        45.6         1(Ref)             
   Intermediate              85(29.0)      17       41.7         2.38(0.70-8.15)    0.166
   Infiltrative              181(61.8)     60       33.9         5.43(1.69-17.45)   0.004
  Borrmann classification                                                           
   Borrmann I--II            82(24.5)      31       60.6         1(Ref)             
   Borrmann III--IV          253(75.5)     81       48.4         1.36(1.09-2.08)    0.015
  Lauren\'s classification                                                          
   Intestinal-type           136(36.9)     34       58.8         1(Ref)             
   Diffuse-type              233(63.1)     78       56.6         0.70(0.46-1.04)    0.078
  TNM stage                                                                         
   I-II                      184(49.3)     18       71.6         1(Ref)             
   III-IV                    189(50.7)     96       41.7         6.92(4.18-11.48)   \<0.001
  Lymphatic metastasis                                                              
   Negative                  145(38.9)     16       70.6         1(Ref)             
   Positive                  228(61.1)     98       48.4         4.69(2.76-7.95)    \<0.001
  Alcohol drinking                                                                  
   Nondrinkers               199(67.9)     55       37.5         1(Ref)             
   Drinkers                  94(32.1)      25       37.0         0.90(0.56-1.45)    0.665
  Smoking                                                                           
   Nonsmokers                183(62.5)     48       37.9         1(Ref)             
   Smokers                   110(37.5)     32       36.8         1.03(0.66-1.62)    0.894

Polymorphisms of NER pathway genes and OS of GC {#s2_2}
-----------------------------------------------

The results of the relation between all polymorphisms of NER pathway and GC survival in different genetic models were summarized in [Supplementary Table S1](#SD2){ref-type="supplementary-material"}. Of the 43 investigated SNPs in this study, six polymorphisms demonstrated significant association with GC survival, including *ERCC1* rs3212961 A/C, *ERCC2* rs50871 G/T, *ERCC5* rs2094258 A/G, *ERCC6* rs1917799 G/T, *DDB2* rs3781619 A/G and *DDB2* rs830083 C/G, which were shown in Table [2](#T2){ref-type="table"}.

###### NER pathway gene polymorphisms that demonstrate significant association with OS of GC

  SNP               Compared Genotype   Patients(%)   Deaths   Crudea                Adjustedb                         
  ----------------- ------------------- ------------- -------- --------------------- ----------- --------------------- -----------
  ERCC1 rs3212961   CC                  92(25.9)      34       ref.                              ref.                  
                    AC                  189(53.2)     53       0.73(0.47-1.12)       0.149       0.67(0.43-1.04)       0.076
                    AA                  74(20.8)      17       **0.52(0.29-0.94)**   **0.031**   **0.54(0.30-0.99)**   **0.045**
                    Dominant                                   0.66(0.44-1.00)       0.050       **0.63(0.41-0.95)**   **0.028**
  ERCC2 rs50871     TT                  125(35.2)     38       ref.                              ref.                  
                    GT                  207(58.3)     54       0.98(0.64-1.49)       0.912       0.89(0.58-1.36)       0.577
                    GG                  23(6.5)       12       **2.54(1.31-4.90)**   **0.006**   1.74(0.86-3.50)       0.121
                    Recessive                                  **2.55(1.39-4.66)**   **0.002**   1.82(0.98-3.38)       0.059
  ERCC5 rs2094258   GG                  149(42.1)     53       ref.                              ref.                  
                    AG                  162(45.8)     39       **0.59(0.39-0.90)**   **0.014**   0.67(0.44-1.03)       0.068
                    AA                  43(12.1)      12       0.68(0.36-1.28)       0.231       0.69(0.36-1.32)       0.262
                    Dominant                                   **0.61(0.42-0.90)**   **0.013**   **0.65(0.44-0.97)**   **0.033**
  ERCC6 rs1917799   TT                  70(32.6)      22       ref.                              ref.                  
                    GT                  105(48.8)     45       1.44(0.86-2.40)       0.162       **1.68(1.01-2.81)**   **0.048**
                    GG                  40(18.6)      15       1.23(0.64-2.37)       0.540       0.95(0.48-1.88)       0.874
                    Dominant                                   1.40(0.85-2.26)       0.191       1.47(0.90-2.41)       0.124
  DDB2 rs3781619    AA                  132(37.2)     34       ref.                              ref.                  
                    AG                  187(52.7)     54       1.18(0.76-1.82)       0.456       1.20(0.77-1.88)       0.419
                    GG                  36(10.1)      16       **2.06(1.13-3.75)**   **0.018**   **2.40(1.27-4.55)**   **0.007**
                    Recessive                                  **1.89(1.11-3.22)**   **0.019**   **2.30(1.33-3.97)**   **0.003**
  DDB2 rs830083     GG                  102(28.8)     32       ref.                              ref.                  
                    CG                  163(46.0)     45       0.66(0.41-1.04)       0.073       **0.61(0.38-0.98)**   **0.042**
                    CC                  89(25.1)      27       0.77(0.46-1.30)       0.324       0.81(0.48-1.38)       0.442
                    Dominant                                   0.70(0.46-1.06)       0.093       0.66(0.43-1.01)       0.056

Calculated by Cox proportional model using univariate analysis.

Calculated by Cox proportional model using multivariate analysis.

Carriers of *ERCC1* rs3212961AA genotype showed significantly favorable OS than wild-type CC genotype both in univariate and multivariate analysis (crude HR=0.52, 95%CI=0.29-0.94, *P*=0.031; adjusted HR=0.54, 95%CI=0.30-0.99, *P*=0.045); After adjustment, patients with the variant AA/AC genotype exhibited longer OS than with those who had CC genotype (HR=0.63, 95%CI=0.41-0.95, *P*=0.028) (Figure [1A](#F1){ref-type="fig"}). For *ERCC2* rs50871 G/T polymorphism, GG genotype subjects demonstrated significantly increased hazards of death in univariate model (GG vs. TT: HR=2.54, 95%CI=1.31-4.90, *P*=0.006; GG vs. (GT+TT): HR=2.55, 95%CI=1.39-4.66, *P*=0.002) (Figure [1B](#F1){ref-type="fig"}). *ERCC5* rs2094258 AG genotype patients were found to have longer OS than wild-type GG carriers in univariate model (HR=0.59, 95%CI=0.39-0.90, *P*=0.014); (AA+AG) genotype individuals revealed significantly favorable survival both in univariate and multivariate analysis compared with GG genotype (crude HR=0.61, 95%CI=0.42-0.90, *P*=0.013; adjusted HR=0.65, 95%CI=0.44-0.97, *P*=0.033) (Figure [1C](#F1){ref-type="fig"}). Patients of *ERCC6* rs1917799 heterozygote GT were associated with significantly shorter OS than TT genotype carriers after adjustments (adjusted HR=1.68, 95%CI=1.01-2.81, *P*=0.048) (Figure [1D](#F1){ref-type="fig"}). Patients with *DDB2* rs3781619 GG genotype suffered higher hazards of death with adjustment of confounding factors (GG vs. AA: HR=2.40, 95%CI=1.27-4.55, *P*=0.007; GG vs. (AG+AA): HR=2.30, 95%CI=1.33-3.97, *P*=0.003) (Figure [1E](#F1){ref-type="fig"}). For *DDB2* rs830083 C/G polymorphism, CG genotype could increase OS compared with GG genotype in multivariate model (HR=0.61, 95%CI=0.38-0.98, *P*=0.042) (Figure [1F](#F1){ref-type="fig"}).
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To limit spurious findings, we attempted to use the Bonferroni correction for multiple comparisons considering significance thresholds for SNP association as *P*=1.16×10^−3^(0.05/43 SNPs). This is a fairly stringent correction given that not all of the SNPs analyzed were independent of each other because of linkage disequilibrium of SNPs. However, most results become not significant after Bonferroni correction.

Polymorphisms of NER pathway genes and OS of GC in different subgroups {#s2_3}
----------------------------------------------------------------------

Stratification analysis was further performed to explore the relation of NER pathway gene polymorphisms and OS of GC in different subgroups. As was displayed in Table [3](#T3){ref-type="table"}, the relation of *ERCC1* rs3212961 with favorable GC survival remained significant in subgroups of female, age≦60, Borrmann I--II, TNM stage III-IV, lymphatic metastasis and intestinal-type. *ERCC2* rs50871 had a better prediction value for worse GC prognosis in subgroups of female and age≦60 after adjustment. (AA+AG) genotype of *ERCC5* rs2094258 polymorphism could predict better OS in patients subgroups of age\>60, Borrmann III--IV, TNM stage III-IV, lymphatic metastasis and diffuse-type. *ERCC6* rs1917799 GT genotype was associated with shorter survival in TNM stage III-IV and smokers. For *DDB2* rs3781619 polymorphism, significant relations were found in subgroups of age≦60, Borrmann III--IV, TNM stage III-IV, lymphatic metastasis and diffuse-type. *DDB2* rs830083 CG genotype could predict favorable survival in males, Borrmann III--IV, TNM stage III-IV, lymphatic metastasis and intestinal-type.

###### Polymorphisms of NER pathway genes and OS of GC in different subgroups

  Variables                            Subgroup           Genotype (deaths/patients)   Crude[^a^](#tfn_003){ref-type="table-fn"}   Adjusted[^b^](#tfn_004){ref-type="table-fn"}                                      
  ------------------------------------ ------------------ ---------------------------- ------------------------------------------- ---------------------------------------------- ----------- ---------------------- -----------
  **ERCC1 rs3212961 (AA+AC) vs. CC**                      **CC**                       **AA+AC**                                                                                                                     
  Age                                  ≦60                20/49                        38/153                                      **0.54(0.31-0.93)**                            **0.026**   **0.54(0.31-0.94)**    **0.028**
                                       \>60               14/43                        32/110                                      0.88(0.47-1.66)                                0.700       0.77(0.41-1.46)        0.425
  Gender                               Male               22/64                        54/189                                      0.77(0.47-1.27)                                0.308       0.72(0.43-1.19)        0.199
                                       Female             12/28                        16/74                                       **0.46(0.22-0.98)**                            **0.043**   **0.45(0.21-0.97)**    **0.043**
  Macroscopic type                     Borrmann I--II     12/23                        11/49                                       **0.33(0.15-0.75)**                            **0.008**   **0.41(0.17-0.97)**    **0.043**
                                       Borrmann III--IV   21/58                        58/189                                      0.82(0.50-1.36)                                0.441       0.74(0.44-1.22)        0.236
  TNM stage                            I-II               5/46                         11/130                                      0.77(0.27-2.22)                                0.629       0.91(0.31-2.69)        0.863
                                       III-IV             29/46                        59/133                                      **0.61(0.39-0.95)**                            **0.028**   **0.59(0.37-0.93)**    **0.023**
  Lymphatic metastasis                 Negative           5/37                         9/102                                       0.64(0.21-1.90)                                0.416       0.82(0.25-2.74)        0.749
                                       Positive           29/55                        61/161                                      **0.63(0.41-0.98)**                            **0.042**   **0.62(0.39-0.97)**    **0.035**
  Lauren\'s classification             Intestinal-type    13/37                        19/93                                       0.55(0.27-1.11)                                0.097       **0.45(0.22-0.95)**    **0.037**
                                       Diffuse-type       20/54                        50/167                                      0.72(0.43-1.22)                                0.223       0.71(0.42-1.21)        0.211
  **ERCC2 rs50871 GG vs. (GT+TT)**                        **GT+TT**                    **GG**                                                                                                                        
  Age                                  ≦60                49/184                       9/18                                        **2.75(1.34-5.64)**                            **0.006**   **2.16(1.04-4.47)**    **0.039**
                                       \>60               43/148                       3/5                                         2.20(0.68-7.13)                                0.189       1.16(0.35-3.83)        0.805
  Gender                               Male               66/233                       10/20                                       **2.22(1.14-4.33)**                            **0.019**   1.46(0.74-2.86)        0.274
                                       Female             26/99                        2/3                                         **8.27(1.84-37.12)**                           **0.006**   **7.88(1.67-37.14)**   **0.009**
  Macroscopic type                     Borrmann I--II     20/68                        3/4                                         **3.74(1.10-12.72)**                           **0.035**   3.18(0.78-12.87)       0.106
                                       Borrmann III--IV   71/229                       8/18                                        1.71(0.82-3.57)                                0.149       1.43(0.68-3.01)        0.346
  Lymphatic metastasis                 Negative           13/131                       1/8                                         2.45(0.32-19.07)                               0.392       1.90(0.21-17.10)       0.567
                                       Positive           79/201                       11/15                                       **2.26(1.20-4.26)**                            **0.011**   1.78(0.93-3.40)        0.081
  Lauren\'s classification             Intestinal-type    28/122                       4/8                                         2.87(1.00-8.23)                                0.050       1.47(0.48-4.49)        0.495
                                       Diffuse-type       62/206                       8/15                                        **2.50(1.19-5.24)**                            **0.015**   1.89(0.88-4.03)        0.102
  **ERCC5 rs2094258 (AA+AG) vs. GG**                      **GG**                       **AA+AG**                                                                                                                     
  Age                                  ≦60                27/79                        31/122                                      0.63(0.37-1.05)                                0.078       0.64(0.37-1.10)        0.106
                                       \>60               26/70                        20/83                                       0.61(0.34-1.09)                                0.095       **0.50(0.28-0.92)**    **0.025**
  Gender                               Male               37/120                       39/150                                      **0.63(0.40-0.98)**                            **0.042**   0.63(0.40-1.00)        0.051
                                       Female             16/47                        12/55                                       0.58(0.27-1.22)                                0.149       0.57(0.26-1.25)        0.160
  Macroscopic type                     Borrmann I--II     10/28                        13/44                                       0.79(0.35-1.80)                                0.569       0.76(0.32-1.79)        0.528
                                       Borrmann III--IV   42/107                       37/139                                      **0.58(0.37-0.91)**                            **0.017**   **0.61(0.39-0.96)**    **0.034**
  TNM stage                            I-II               4/69                         12/107                                      1.84(0.59-5.72)                                0.289       1.91(0.60-6.02)        0.271
                                       III-IV             49/80                        39/98                                       **0.54(0.35-0.82)**                            **0.004**   **0.53(0.34-0.82)**    **0.004**
  Lymphatic metastasis                 Negative           6/60                         8/79                                        0.89(0.31-2.56)                                0.823       1.04(0.36-3.10)        0.951
                                       Positive           47/89                        43/126                                      **0.55(0.36-0.83)**                            **0.005**   **0.62(0.40-0.94)**    **0.025**
  Lauren\'s classification             Intestinal-type    14/50                        18/79                                       0.80(0.40-1.62)                                0.540       1.03(0.50-2.12)        0.943
                                       Diffuse-type       39/97                        31/124                                      **0.51(0.32-0.82)**                            **0.006**   **0.51(0.31-0.83)**    **0.007**
  **ERCC6 rs1917799 GT vs. TT**                           **TT**                       **GT**                                                                                                                        
  Macroscopic type                     Borrmann I--II     11/26                        13/32                                       1.03(0.46-2.29)                                0.948       0.83(0.36-1.94)        0.669
                                       Borrmann III--IV   11/37                        31/56                                       **2.03(1.02-4.04)**                            **0.044**   **2.42(1.20-4.87)**    **0.014**
  Smoking                              Nonsmokers         7/30                         16/41                                       1.73(0.71-4.21)                                0.227       2.06(0.84-5.03)        0.114
                                       Smokers            4/18                         14/32                                       2.11(0.69-6.41)                                0.189       **4.10(1.19-14.06)**   **0.025**
  **DDB2 rs3781619 GG vs. (AG+AA)**                       **AG+AA**                    **GG**                                                                                                                        
  Age                                  ≦60                47/178                       11/24                                       **2.16(1.12-4.19)**                            **0.022**   **3.16(1.55-6.43)**    **0.001**
                                       \>60               41/141                       5/12                                        1.41(0.56-3.57)                                0.469       1.45(0.56-3.77)        0.446
  Macroscopic type                     Borrmann I--II     19/65                        4/7                                         2.12(0.72-6.23)                                0.172       2.84(0.92-8.75)        0.069
                                       Borrmann III--IV   68/223                       11/24                                       1.83(0.96-3.47)                                0.065       **2.02(1.05-3.89)**    **0.035**
  TNM stage                            I-II               13/156                       3/20                                        2.36(0.67-8.29)                                0.181       2.60(0.66-10.20)       0.171
                                       III-IV             75/163                       13/16                                       **2.08(1.15-3.76)**                            **0.015**   **2.05(1.09-3.84)**    **0.026**
  Lymphatic metastasis                 Negative           11/119                       3/20                                        2.09(0.58-7.50)                                0.260       2.19(0.57-8.45)        0.254
                                       Positive           77/200                       13/16                                       **2.66(1.47-4.79)**                            **0.001**   **2.23(1.21-4.11)**    **0.010**
  Lauren\'s classification             Intestinal-type    30/123                       2/7                                         1.33(0.32-5.56)                                0.700       3.45(0.74-16.12)       0.115
                                       Diffuse-type       56/192                       14/29                                       **1.91(1.06-3.43)**                            **0.032**   **2.03(1.10-3.75)**    **0.024**
  **DDB2 rs830083 CG vs. GG**                             **GG**                       **CG**                                                                                                                        
  Gender                               Male               30/75                        30/121                                      **0.42(0.25-0.71)**                            **0.001**   **0.45(0.26-0.76)**    **0.003**
                                       Female             2/27                         15/42                                       **4.51(1.03-19.81)**                           **0.046**   3.44(0.75-15.68)       0.111
  Macroscopic type                     Borrmann I--II     5/16                         15/37                                       1.34(0.49-3.68)                                0.573       1.07(0.38-3.03)        0.905
                                       Borrmann III--IV   25/78                        30/111                                      **0.56(0.32-0.97)**                            **0.038**   **0.56(0.33-0.98)**    **0.041**
  TNM stage                            I-II               3/54                         8/78                                        1.03(0.27-3.94)                                0.970       1.16(0.29-4.74)        0.834
                                       III-IV             29/48                        37/85                                       **0.56(0.34-0.91)**                            **0.019**   **0.58(0.35-0.97)**    **0.039**
  Lymphatic metastasis                 Negative           3/44                         7/65                                        0.98(0.25-3.89)                                0.981       0.85(0.20-3.60)        0.825
                                       Positive           29/58                        38/98                                       **0.59(0.36-0.96)**                            **0.032**   **0.60(0.36-0.99)**    **0.045**
  Lauren\'s classification             Intestinal-type    9/35                         16/65                                       0.54(0.23-1.26)                                0.154       **0.30(0.12-0.79)**    **0.015**
                                       Diffuse-type       23/67                        29/97                                       0.75(0.43-1.30)                                0.306       0.81(0.46-1.43)        0.467

Calculated by Cox proportional model using univariate analysis.

Calculated by Cox proportional model using multivariate analysis.

Polymorphisms of NER pathway genes and OS of GC in patients who received postoperative chemotherapy {#s2_4}
---------------------------------------------------------------------------------------------------

We then performed survival analysis for patients who received postoperative chemotherapy to investigate whether chemotherapy had influence on the association between polymorphisms of NER pathway genes and OS of GC. Altogether 94 patients received chemotherapy after surgery. The results indicated that carriers of *ERCC2* rs50871GG genotype showed significantly unfavorable OS than (GT+TT) genotype both in univariate and multivariate analysis (crude HR=3.48, 95%CI=1.16-10.44, *P*=0.026; adjusted HR=5.36, 95%CI=1.69-17.03, *P*=0.004); Patients with *DDB2* rs3781619 GG genotype suffered higher hazards of death with adjustment (GG vs. AA: HR=10.30, 95%CI=1.11-95.80, *P*=0.040; GG vs. (AG+AA): HR=6.73, 95%CI=1.20-37.61, *P*=0.030) ([Supplementary Table S2](#SD1){ref-type="supplementary-material"}).

Joint effect of NER pathway gene polymorphisms on OS of GC {#s2_5}
----------------------------------------------------------

To investigate whether the combined detection of certain NER pathway polymorphisms could better predict the survival of GC, we further performed joint analysis of single NER polymorphism which demonstrated significant association (Table [4](#T4){ref-type="table"}). The results indicated that patients simultaneously carrying two "hazard" genotypes exhibited even more significantly shorter OS (Figure [2A](#F2){ref-type="fig"}): carriers of both *ERCC2* rs50871 GG and *ERCC6* rs1917799 GT genotypes suffered a 3.75-fold increased hazards of death (*P*=0.019). Similarly, patients with both *ERCC2* rs50871 GG and *DDB2* rs3781619 GG genotypes (HR=6.30, *P*=0.001), with both *ERCC6* rs1917799 GT and *DDB2* rs3781619 GG genotypes (HR=3.76, *P*=0.006) showed significant worse survival.

![Combined detection of NER pathway polymorphisms could more effectively predict survival of gastric cancer patients\
(**A.** combined detection of polymorphisms that could predict worse survival; **B.** combined detection of polymorphisms that could predict favorable survival).](oncotarget-07-48130-g002){#F2}

###### Joint effect of NER pathway gene polymorphisms on OS of GC

  Combined Genotype                           Patients(%)   Deaths   Crude[^a^](#tfn_005){ref-type="table-fn"}   Adjusted[^b^](#tfn_006){ref-type="table-fn"}                          
  --------------------- --------------------- ------------- -------- ------------------------------------------- ---------------------------------------------- ---------------------- -----------
  **ERCC2 rs50871**     **ERCC6 rs1917799**                                                                                                                                            
  GT+TT                 TT                    61(37.7)      18       ref.                                                                                       ref.                   
  GG                    TT                    4(2.5)        2        1.79(0.41-7.75)                             0.439                                          0.98(0.21-4.65)        0.979
  GT+TT                 GT                    90(55.6)      36       1.38(0.79-2.44)                             0.261                                          1.57(0.89-2.78)        0.120
  GG                    GT                    7(4.3)        5        **4.00(1.47-10.90)**                        **0.007**                                      **3.75(1.24-11.32)**   **0.019**
  **ERCC2 rs50871**     **DDB2 rs3781619**                                                                                                                                             
  GT+TT                 AA+AG                 301(84.8)     80       ref.                                                                                       ref.                   
  GG                    AA+AG                 18(5.1)       8        2.03(0.98-4.21)                             0.056                                          1.54(0.73-3.25)        0.256
  GT+TT                 GG                    31(8.7)       12       1.60(0.87-2.93)                             0.132                                          **1.97(1.06-3.67)**    **0.032**
  GG                    GG                    5(1.4)        4        **7.16(2.57-19.93)**                        **1.65×10^−4^**                                **6.30(2.19-18.18)**   **0.001**
  **ERCC6 rs1917799**   **DDB2 rs3781619**                                                                                                                                             
  TT                    AA+AG                 58(35.8)      16       ref.                                                                                       ref.                   
  GT                    AA+AG                 87(53.7)      34       1.47(0.81-2.66)                             0.204                                          1.70(0.94-3.10)        0.082
  TT                    GG                    7(4.3)        4        2.33(0.78-6.99)                             0.131                                          1.95(0.58-6.61)        0.282
  GT                    GG                    10(6.2)       7        **3.16(1.30-7.69)**                         **0.011**                                      **3.76(1.47-9.63)**    **0.006**
  **ERCC1 rs3212961**   **ERCC5 rs2094258**                                                                                                                                            
  CC                    GG                    39(11.0)      16       ref.                                                                                       ref.                   
  AA+AC                 GG                    110(31.1)     37       0.70(0.39-1.26)                             0.234                                          0.58(0.30-1.11)        0.099
  CC                    AA+AG                 53(15.0)      18       0.68(0.35-1.35)                             0.272                                          0.69(0.32-1.48)        0.343
  AA+AC                 AA+AG                 152(42.9)     33       **0.42(0.23-0.76)**                         **0.004**                                      **0.33(0.17-0.63)**    **0.001**
  **ERCC1 rs3212961**   **DDB2 rs830083**                                                                                                                                              
  CC                    GG                    27(10.2)      10       ref.                                                                                       ref.                   
  AA+AC                 GG                    75(28.3)      22       0.78(0.37-1.65)                             0.516                                          0.89(0.40-1.99)        0.779
  CC                    CG                    49(18.5)      16       0.68(0.31-1.51)                             0.343                                          0.69(0.29-1.66)        0.407
  AA+AC                 CG                    114(43.0)     29       0.51(0.25-1.06)                             0.070                                          0.56(0.26-1.20)        0.135
  **ERCC5 rs2094258**   **DDB2 rs830083**                                                                                                                                              
  GG                    GG                    41(15.5)      14       ref.                                                                                       ref.                   
  AA+AG                 GG                    60(22.7)      18       0.88(0.44-1.78)                             0.727                                          0.88(0.42-1.86)        0.733
  GG                    CG                    66(25.0)      22       0.83(0.41-1.63)                             0.589                                          0.79(0.37-1.67)        0.537
  AA+AG                 CG                    97(36.7)      23       **0.49(0.25-0.96)**                         **0.038**                                      **0.49(0.24-1.00)**    **0.048**

Calculated by Cox proportional model using univariate analysis.

Calculated by Cox proportional model using multivariate analysis.

The combination of single NER polymorphism predicting better prognosis also revealed even more favorable survival (Figure [2B](#F2){ref-type="fig"}): *ERCC1* rs3212961 AA/AC and *ERCC5* rs2094258 AA/AG genotypes carriers had a significant longer OS (HR=0.33, 95%CI=0.17-0.63, *P*=0.001); individuals with both *ERCC5* rs2094258 AA/AG and *DDB2* rs830083 CG genotypes were associated with significantly increased OS (HR=0.49, 95%CI=0.24-1.00, *P*=0.048). It was therefore obvious that combined detection of two core NER pathway gene polymorphisms could more effectively predict GC survival.

DISCUSSION {#s3}
==========

Identifying biomarkers associated with GC survival is essential for the individualized therapy and post-operational treatment for different patients. Although several previous studies have revealed that NER gene polymorphisms could alter GC survival, to the best of our knowledge this is the first comprehensive investigation of the relationship between polymorphisms of the entire NER pathway and prognosis of GC. In this study, 43 SNPs of ten NER pathway genes were investigated in relation to OS of GC patients. We for the first time found that *ERCC2* rs50871 G/T, *ERCC6* rs1917799 G/T, *DDB2* rs3781619 A/G polymorphisms were significantly associated with shorter OS while *ERCC1* rs3212961 A/C, *ERCC5* rs2094258 A/G, *DDB2* rs830083 C/G could predict favorable OS of GC patients in Chinese. In addition, the combined detection of NER pathway gene polymorphisms could more effectively predict the prognosis of GC.

NER process includes steps of damage recognition, damage demarcation and unwinding, damage incision, and new strand ligation \[[@R22], [@R23]\]. Multiple genes are involved in this pathway and in charge of different functions \[[@R24]\]: XPA, XPC and DDB2 are responsible for the DNA damage recognition; ERCC2 and ERCC3 participate in the damage unwinding process; ERCC1, ERCC4 and ERCC5 are involved in the DNA damage incision; ERCC6 and ERCC8 are both essential factors involved in transcription-coupled NER. In this study, we found that *ERCC2* rs50871 GG, *ERCC6* rs1917799 GT and *DDB2* rs3781619 GG genotypes indicated worse OS of GC. The results for *ERCC2* rs50871 was opposite to the previous findings in melanoma \[[@R25]\] or head and neck cancer \[[@R26]\], in which the GG genotype was related to favorable survival. *ERCC6* rs1917799 was previously linked to increased risk of GC \[[@R27]\], but its role in GC prognosis has not been studied before. In this study, *ERCC6* rs1917799 heterozygote GT was firstly found to be associated with significantly shorter OS than wild-type TT. In addition, we found that *ERCC1* rs3212961 AA/AC, *ERCC5* rs2094258 AA/AG and *DDB2* rs830083 CG genotypes could predict favorable OS. After analyzing patients who received postoperative chemotherapy, we found that *ERCC2* rs50871 and *DDB2* rs3781619 polymorphisms were significantly associated with worse OS. However, due to the limited number of patients who received chemotherapy, the detailed role of chemotherapy in the relation between NER pathway polymorphisms and GC prognosis stilled need further investigations.

Among these newly discovered polymorphisms which could predict GC survival, *ERCC5* rs2094258 and *ERCC6* rs1917799 were both located in the 5′ upstream regulatory region, which may influence the binding activity of certain transcriptional factor, thus altering the expression and function of corresponding NER factors. *ERCC1* rs3212961, *ERCC2* rs50871, *DDB2* rs3781619 and *DDB2* rs830083 were all located in the intron region of genes. Sequence variation of introns especially the polymorphic site which changes alternative splicing patterns hold great promise in altering the regulation of the gene\'s transcription and thereby modulating function of specific factors of NER pathway \[[@R28]\]. By this way, these polymorphisms of NER pathway genes may modulate the DRC phenotype. The alteration in the NER capacity may in turn change frequencies of DNA mutation due to unrepaired damaged DNA. Thus, it is biologically plausible that polymorphisms in NER genes may influence clinical outcomes in GC patients. Furthermore, it is notable that the polymorphisms which demonstrated significant associations with GC survival are located within different genes responsible for each step of NER process: *DDB2* of "damage recognition" step, *ERCC2* of "damage unwinding" step, *ERCC1* and *ERCC5* of "damage incision" step. This interesting phenomenon suggested that each step of the NER process was important for the role of NER in GC prognosis. Although the above-mentioned mechanisms might, at least in part, explained the observed significant associations of certain NER polymorphisms and GC survival, further molecular researches are still needed to reveal the underlying mechanism.

As a complicated and multi-step process, NER pathway factors might function jointly to alter GC prognosis, and a single polymorphism may be insufficient to predict GC survival. Therefore, on the basis of our findings of certain relations between single polymorphism and GC survival, we further explored whether the combined detection of certain NER pathway gene polymorphisms could better predict the survival of GC through joint analysis of single NER polymorphism which demonstrated significant association with GC survival. The findings suggested that patients simultaneously carrying two "hazard" genotypes exhibited even more significantly worse OS: carriers of both *ERCC2* rs50871 GG and *ERCC6* rs1917799 GT genotypes suffered a 3.75-fold increased hazards of death; patients with both *ERCC2* rs50871 GG and *DDB2* rs3781619 GG genotypes (HR=6.30), with both *ERCC6* rs1917799 GT and *DDB2* rs3781619 GG genotypes (HR=3.76) showed significant worse OS. Similarly, the combination of single NER polymorphism predicting better prognosis also revealed even more favorable survival: *ERCC1* rs3212961 AA/AC and *ERCC5* rs2094258 AA/AG genotypes carriers had a significant longer survival (HR=0.33); individuals with both *ERCC5* rs2094258 AA/AG and *DDB2* rs830083 CG genotypes were associated with significantly increased OS (HR=0.49). Therefore, it was obvious that combined detection of two core NER pathway polymorphisms could more effectively predict GC survival. These results might due to the interaction or joint effect of polymorphisms of different factors involved in NER pathway. It is promising that the joint detection of different polymorphisms of NER pathway could be applied in the prediction of the prognosis of GC.

Several limitations should be acknowledged in this study. Considering the availability of our data, we could only get the information that whether the patients received chemotherapy after surgery rather than detailed chemotherapeutic information. Secondly, the sample size of this study was relatively insufficient especially for the subgroup analysis, which requires future studies based on large population to confirm. Thirdly, most results became not significant after Bonferroni correction which required stricter significance. Bonferroni correction might be a fairly stringent correction given that not all of the SNPs analyzed were independent of each other because of linkage disequilibrium of SNPs. We therefore considered the results of this study as preliminary screening and exploration, which provide direction for future studies concerning NER pathway and GC prognosis.

Our study for the first time unravelled the promising role of NER pathway gene polymorphism as a prognosis biomarker from the perspective of the entire pathway. Such NER pathway gene polymorphisms would largely benefit the management strategy for GC patients, making it possible to enhance the follow-up and dynamic monitoring for GC individuals with the specific genotype of certain polymorphisms.

In summary, our findings demonstrated that *ERCC2* rs50871 G/T, *ERCC6* rs1917799 G/T, *DDB2* rs3781619 A/G polymorphisms were significantly associated with shorter OS of GC; *ERCC1* rs3212961 A/C, *ERCC5* rs2094258 A/G, *DDB2* rs830083 C/G could predict favorable OS of GC patients in Chinese. Joint detection of *ERCC2* rs50871, *ERCC6* rs1917799 and *DDB2* rs3781619 could more efficiently predict worse OS while combined detection of *ERCC1* rs3212961, *ERCC5* rs2094258 and *DDB2* rs830083 could predict even better OS. Therefore, polymorphisms of multiple genes involved in NER pathway might serve as promising biomarkers to predict prognosis of gastric cancer.

MATERIALS AND METHODS {#s4}
=====================

Study subjects {#s4_1}
--------------

This study project was approved by the Institute Research Medical Ethics Committee of the First Affiliated Hospital of China Medical University. A total of 373 GC patients were recruited from the Department of Surgical Oncology of the First Affiliated Hospital of China Medical University between 2008 and 2013. Written informed consents were obtained from participants. Medical histories were acquired by questionnaire and the records were computerized. All the GC patients were histopathologically confirmed and classified based on current Borrmann and Lauren\'s classification. Tumors were staged using the 7th edition of the TNM staging system of the International Union Against Cancer (UICC)/American Joint Committee on Cancer (AJCC) (2010) according to postoperative pathologic examination. Patients who (i) had other malignant tumours (ii) distant metastasis found preoperatively (iii) underwent preoperative radiotherapy or chemotherapy were excluded from this study. And the prognostic parameter is overall survival (OS) in this study. OS was calculated up to either the date of death or last clinical follow-up, whichever occurred first. Patients without death at the time of the analysis were censored at the date of the last follow-up. The follow-up of the patients was completed by September 2014.

Candidate genes and SNP selection {#s4_2}
---------------------------------

Genotype data from extended NER pathway gene regions encompassing 5 kb of upstream and downstream flanking sequences were extracted from the HapMap Chinese Han Beijing population (Release 27, Phase I + II + III, [http://www.HapMap.org](http://www.hapmap.org/)). Haploview software (<http://www.broadinstitute.org/mpg/haploview>) was used to minimize the number of SNPs needed to be genotyped, providing a significant shortcut to carry out candidate gene association studies in a particular population. Tag SNPs were selected on the basis of pairwise linkage disequilibrium information to maximally capture (r^2^ \> 0.8) common or rare variants (minor allele frequency \[MAF\] \> 0.05) by Haploview 4.2. FastSNP Search was used to predict the potential SNP function (leading to amino acid substitutions, altering splicing or transcription factor-binding motifs, acting as intronic enhancers) \[[@R29], [@R30]\]. Totally 43 SNPs covering ten key NER pathway genes (*ERCC1*, *ERCC2*, *ERCC3*, *ERCC4*, *ERCC5*, *ERCC6*, *ERCC8*, *XPA*, *XPC*, and *DDB2*) were eventually chosen by integrating these two publicly available tools. The detailed information of selected SNPs from NER pathway genes was shown in Table [5](#T5){ref-type="table"}.

###### Detailed information of 43 genotyped SNPs in NER pathway

  Gene    dbSNP number   Base change   SNP location             MAF     
  ------- -------------- ------------- ------------------------ ------- -------
  ERCC1   rs11615        C\>T          Exon                     0.243   0.241
          rs2298881      C\>A          Promoter                 0.444   0.399
          rs3212955      A\>G          Intron                   0.289   0.300
          rs3212961      C\>A          Intron                   0.453   0.475
          rs3212986      G\>T          3′ Untranslated region   0.310   0.330
          rs735482       A\>C          3′ Untranslated region   0.427   0.435
  ERCC2   rs1052555      C\>T          Exon                     0.104   0.068
          rs13181        T\>G          Exon                     0.095   0.082
          rs238406       G\>T          Exon                     0.407   0.461
          rs238417       G\>C          Intron                   0.488   0.461
          rs50871        T\>G          Intron                   0.279   0.356
          rs50872        C\>T          Intron                   0.190   0.221
  ERCC3   rs4150441      G\>A          Intron                   0.444   0.424
          rs4150448      G\>A          Intron                   0.109   0.110
          rs4150506      C\>T          Intron                   0.320   0.307
  ERCC4   rs6498486      A\>C          5′ Upstream              0.282   0.225
          rs1799801      T\>C          Exon                     0.237   0.210
          rs2276464      G\>C          3′ Untranslated region   0.275   0.207
          rs254942       T\>C          Intron                   0.241   0.215
  ERCC5   rs1047768      T\>C          Exon                     0.241   0.312
          rs2094258      G\>A          Promoter                 0.383   0.350
          rs2228959      C\>A          Exon                     0.062   0.046
          rs2296147      T\>C          5′ Upstream              0.201   0.218
          rs4150291      A\>T          Intron                   0.081   0.100
          rs4150383      G\>A          Intron                   0.088   0.063
          rs751402       C\>T          Promoter                 0.367   0.359
          rs873601       G\>A          3′ Untranslated region   0.496   0.479
  ERCC6   rs1917799      T\>G          5′ Upstream              0.303   0.430
  ERCC8   rs158572       A\>G          Intron                   0.306   0.107
          rs158916       T\>C          5′ Upstream              0.152   0.121
  XPA     rs10817938     T\>C          5′ Upstream              0.208   0.236
          rs2808668      T\>C          Intron                   0.478   0.499
          rs3176629      C\>T          Promoter                 0.088   0.096
          rs3176658      C\>T          Intron                   0.256   /
  XPC     rs1870134      G\>C          5′ Upstream              0.244   0.269
          rs2228000      C\>T          Exon                     0.325   0.312
          rs2228001      A\>C          Exon                     0.372   0.375
          rs2470352      A\>T          3′ UTR                   0.058   0.007
          rs2607775      C\>G          5′ Upstream              0.089   0.049
  DDB2    rs2029298      G\>A          Promoter                 0.354   0.324
          rs326222       T\>C          Intron                   0.274   0.268
          rs3781619      A\>G          Intron                   0.383   0.365
          rs830083       C\>G          Intron                   0.367   0.482

MAF for Chinese in Hapmap database ([www.hapmap.org](http://www.hapmap.org/))

Abbreviations: MAF, minor allele frequency; GC, gastric cancer.

Genotyping assay {#s4_3}
----------------

Genomic DNA was isolated from blood samples by routine phenol--chloroform extraction and then diluted into working concentrations (50 ng/μl) for further genotyping. Samples were placed randomly on the 384-well plates and blinded for the status of disease. The design of the assay and SNP genotyping were performed by Bio Miao Biological Technology (Beijing, China) using the Sequenom MassARRAY platform (Sequenom, San Diego, CA) according to the manufacturer\'s instructions. The results of all duplicated samples were 100% consistent.

Statistical analysis {#s4_4}
--------------------

Statistical analysis was performed by using SPSS (16.0) statistical software (SPSS, Chicago, IL, USA). The Kaplan-Meier method was applied to visualize overall survival (OS) by different genotype groups. The median survival time (MST) was calculated; mean survival time was chosen if the median survival time could not be calculated. The log-rank test was used to test for equality of the survival distributions. Univariate and multivariate Cox proportional hazards models were performed to calculate crude or adjusted hazards ratios (HR) and 95% confidence intervals (CI) of each genotype to estimate its effect on OS with or without adjustment for confounding factors. Significant variables in univariate models were further analyzed by multivariate Cox proportional hazards regression models to identify the independent prognostic value. Two-tailed *P* values \< 0.05 were considered statistically significant.
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